Sangamo Biosciences Inc (SGMO)

[Fress]

SGMO - BIIB Global Neuro Deal Validates ZNF Gene Editing - BUY - In one of the largest preclinical deals in biotech history, Biogen will pay Sangamo $350 million upfront and up to very achievable $2.37 billion in potential milestones. The deal vindicates and validates SGMO’s ZNF platform in gene editing, which most investors have written off. With current cash ~$700 million, SGMO is cheaper than ever to us on multiple valuation methodologies, either as a standalone and even so when compared to other gene editing stocks.


$SGMO